8-K: Protagenic Therapeutics Stockholders Approve Option Repricing, Board Executes

Protagenic Therapeutics' stockholders approved the repricing of outstanding stock options, and the Board subsequently repriced the options to $0.2655 per share.

Summary

• Protagenic Therapeutics held its 2024 Annual Meeting of Stockholders on February 21, 2025.
• Stockholders approved a proposal to allow the Board of Directors to reprice certain outstanding stock options granted under the company's 2006 and 2016 Equity Incentive Plans.
• On February 21, 2025, the Board repriced the Option Grants.
• Original exercise prices for options under the 2006 plan ranged from $4.00 to $5.00 per share.
• Original exercise prices for options under the 2016 plan ranged from $1.74 to $19.92 per share.
• All options were repriced to an exercise price of $0.2655 per share, which was the closing price of the company's common stock on February 21, 2025.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document primarily reports on the approval and execution of a stock option repricing. The impact can be viewed as both positive (incentivizing employees) and negative (dilution).

Positives

• The repricing of stock options may incentivize employees and align their interests with those of the shareholders.

Negatives

• The repricing of stock options to a lower price dilutes the value of existing shares.

Risks

• The repricing of stock options could be perceived negatively by some investors if it is seen as a way to benefit employees at the expense of shareholders.

Industry Context

Repricing stock options is a common practice among companies, especially when the stock price has declined significantly, to retain and motivate employees.

Stakeholder Impact

• Shareholders may experience dilution due to the repricing of stock options.
• Employees holding stock options will benefit from the lower exercise price.

Key Dates

Keywords

stock options, repricing, equity incentive plans, annual meeting, Protagenic Therapeutics, PTIX, PTIXW